Media coverage about Transition Therapeutics (NASDAQ:TTHI) (TSE:TTH) has been trending positive recently, Accern Sentiment reports. Accern ranks the sentiment of news coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Transition Therapeutics earned a media sentiment score of 0.30 on Accern’s scale. Accern also gave media headlines about the biopharmaceutical company an impact score of 43.6735228611644 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
Transition Therapeutics Company Profile
Transition Therapeutics Inc is a product-focused biopharmaceutical company. The Company’s principal business activity is the researching and developing of therapeutic agents. The Company is developing therapeutics for central nervous system (CNS) and metabolic disease indications. The Company’s technologies are focused on the treatment of agitation and aggression in Alzheimer’s disease and diabetes.
Receive News & Ratings for Transition Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Transition Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.